Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab (CS1001) Plus Low-Dose Radiation in Relapsed Small Cell Lung Cancer
NCT04421352Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of sugemalimab in small cell lung cancer (SCLC) (3 arms), sponsored by CStone Pharmaceuticals. Primary endpoints: Recommended radiation dose at 2 years and Anti-tumor efficacy at 2 years. Started Jan 2021; status: completed.
02
Drugs
sugemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04421352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421352.